Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s63, 2022. DOI: 10.25251/skin.6.supp.63. Disponível em: https://skin.dermsquared.com/skin/article/view/1818. Acesso em: 17 apr. 2026.